文献速递核素与放射性配体治疗放射性药物与辐射防护

PRRT后治疗相关髓系肿瘤:1631例20年经验中的预后参数与总生存

Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-11-27

该研究回顾性纳入1999年2月至2019年9月在本中心接受PRRT后经骨髓活检证实为t-MN的30例患者,其中MDS 23例(77%)、AML 7例(23%)。t-MN患者中位OS为13个月(范围9.1–16.9个月),AML亚组为6个月、MDS亚组为15个月;较高血小板水平与更长OS显著相关(HR 0.99,P<0.05)。

要点

  • PRRT后t-MN虽罕见,但患者总生存严重受损,AML亚组中位OS仅6个月。
  • t-MN患者中位OS为13个月,MDS亚组为15个月。
  • 较高血小板水平是更长OS的显著预后参数(HR 0.99,P<0.05)。

核心结论

  • PRRT后t-MN虽罕见发生,但患者OS严重受损,AML亚组更差(6个月)。
  • 较高血小板值是t-MN患者更长OS的显著预后参数。

研究设计与样本

  • 回顾性纳入1999年2月至2019年9月在本中心接受PRRT后经骨髓活检证实为t-MN的患者。
  • 共1631例接受PRRT的患者中30例发生t-MN,包括MDS 23例(77%)和AML 7例(23%)。
  • 收集患者特征、实验室结果及t-MN诊断前所有肿瘤导向治疗,采用Cox回归分析OS相关参数,ROC曲线确定截断值及敏感性和特异性。

主要发现

  • t-MN患者中位OS为13个月(范围9.1–16.9个月),AML亚组为6个月,MDS亚组为15个月。
  • 较高血小板水平与更长OS显著相关(HR 0.99,P<0.05)。
  • 血红蛋白水平等其他因素与OS无显著相关性。

关键数值与推荐

  • 血小板计数ROC分析最佳截断值为183.5 Gpt/L,敏感性92.3%,特异性50%。

临床怎么用

  • PRRT后应警惕t-MN发生,尤其AML亚组预后极差。
  • 血小板水平可用于t-MN患者预后分层,较高血小板提示更长OS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine prognostic factors and overall survival (OS) in therapy-related myeloid neoplasm (t-MN) of patients after receiving peptide receptor radionuclide therapy (PRRT). METHODS: All patients treated from February 1999 until September 2019 at our center who had bone marrow biopsy-proven t-MN after PRRT were included. Patient characteristics, laboratory results, and all tumor-directed therapies before t-MN diagnosis were collected. Cox regression analysis was performed to identify parameters associated with OS. Receiver operating characteristic (ROC) curve analysis was used to define cutoff values as well as sensitivity and specificity of the parameters. RESULTS: Out of 1631 patients treated with PRRT, 30 patients developed t-MN comprising myelodysplastic syndrome (MDS) in 23 patients (77%) and acute myeloid leukemia (AML) in 7 patients (23%). The median OS of t-MN patients was 13 months (range 9.1-16.9 months): 6 months for AML and 15 months for the MDS subgroup, respectively. Higher platelet level was a significant prognostic parameter for longer OS (hazard ratio (HR): 0.99, P < 0.05). Using ROC analysis, the best cutoff value for thrombocyte count was 183.5 Gpt/L, resulting in a sensitivity of 92.3% and a specificity of 50%. Other factors, such as hemoglobin level, did not show a significant correlation with OS. CONCLUSION: Even rarely occurred, the OS is gravely compromised in t-MN patients after PRRT, and even less in the AML subgroup (6 months). Higher platelet value was a significant prognostic parameter for longer OS in t-MN patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chantadisai M, Kulkarni HR, Baum RP, et al. Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival. Eur J Nucl Med Mol Imaging. 2020. PMID: 33247328. doi:10.1007/s00259-020-05127-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。